Building Pillars of Knowledge in Supportive Care: Focus on Bone Health

MEDIA:
Audio/slides with interactive questions. Live Faculty Q&A. Printable PDF also available.

TARGET AUDIENCE
The educational series is intended for nurses, pharmacists and others with clinical, research, and management interests in the treatment of bone health in cancer.

STATEMENT OF NEED
Although patients with cancer are living longer—thanks to scientific advances, promising drug and procedural discoveries, and actual cures—cancer survivors, particularly those with bone metastases, may face other complications following or during the course of their disease.  Moreover, bone loss is particularly challenging because it may be asymptomatic.  Skeletal related events resulting from bone metastases can create a downward spiral in terms of the patient’s health, quality of life, and the cost to society.  The approach to managing bone health in cancer is changing and represents a challenge for the clinicians and many clinicians are currently unaware or insufficiently knowledgeable about advances in the field that may benefit their patients.

EDUCATIONAL OBJECTIVES
On completion of this activity, participants should be able to:

• Describe the potentially serious consequences of skeletal-related events (SREs) associated with cancer and cancer-related treatments
• Review recent advances in the management of bone health in cancer patients, with emphasis on treatment with the bisphosphonates and denosumab
• Examine approaches for improving bone health and outcomes for patients with skeletal complications, based on key clinical evidence and practice guidelines

AGENDA:

• Introduction (5 minutes)
• Review ofskeletal-related events (SREs) associated with cancer and cancer-related treatments (15 minutes)
• Discuss recent advances in the management of bone health in cancer patients and the implications here of (15 minutes)
• “Solve” clinical case studies based on key clinical evidence and practice guidelines (10 minutes)
• Live faculty Q& A (10 minutes)
• Evaluation and posttest (5 minutes)

FACULTY
Regina Cunningham, PhD, RN, AOCN
Senior Director Oncology
The Tisch Cancer Institute
Mount Sinai Medical Center
New York, NY

Dr. Cunningham has disclosed that she serves on speakers’ bureau for Merck.

R. Donald Harvey, PharmD, FCCP, BCPS, BCOP
Assistant Professor, Hematology/Medical Oncology
Director, Phase I Unit
Winship Cancer Institute
Emory University School of Medicine
Atlanta, GA

Dr. Harvey has no financial relationships to disclose relating to the content of this activity.

The planners and managers have no financial or other relationship to products or devices with commercial interests related to the content of this CE/CME activity.

INSTRUCTIONS
To receive a statement of credit, you must:

• Review the full content of the activity
• Complete the questions within the activity
• Complete the evaluation at the end of the activity.

ACCREDITATION STATEMENTS
PHARMACY

Creative Educational Concepts, Inc. (CEC) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This knowledge-based activity has been assigned ACPE # 0245-0000-11-015-H01-P and will award 1.0 contact hour (0.10 CEUs) of continuing pharmacy education credit. CEC complies with the Criteria for Quality for continuing education programming.

NURSING
Creative Educational Concepts, Inc. (CEC) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

CEC provides this activity for 1.0 contact hour.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

Your statement of credit will be issued immediately upon successful completion of the posttest and evaluation form.

FEE
This activity is complimentary.

DISCLOSURE DECLARATION
It is the policy of CEC, Astute CE and COE to ensure independence, balance, objectivity, scientific rigor, and integrity in their continuing education activities.

Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer's package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.

Fair balance is achieved through ongoing and thorough review of all presentation materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by CEC for any product or manufacturer identified.

UNLABELED USE DISCLOSURE
This activity may include discussions of products or devices that are not currently approved for use by the Food and Drug Administration (FDA), or are currently investigational.

This activity is jointly sponsored by Creative Educational Concepts, Inc., Center of Excellence Media, LLC, and Astute Continuing Education, LLC.

SUPPORTING ORGANIZATION:
This activity is supported by an independent educational grant from Amgen, Inc.

REQUIRED COMPUTER HARDWARE/SOFTWARE: